Adaptive Biotechnologies Announces Over 65 Abstracts Featuring ClonoSEQ MRD Testing Across a Range of Blood Cancers to Be Presented at the 66th ASH Annual Meeting
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring ClonoSEQ MRD Testing Across a Range of Blood Cancers to Be Presented at the 66th ASH Annual Meeting
A complete list of the accepted abstracts featuring clonoSEQ is available here.SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2024, in San Diego. Among these abstracts are a plenary session presentation, a late-breaking abstract and 25 other oral presentations.
西雅图，2024年12月03日（全球新闻通讯）-- adaptive biotechnologies 公司（纳斯达克：ADPT）是一家商业阶段的生物技术公司，旨在将适应性免疫系统的遗传学转化为临床产品，以诊断和治疗疾病。该公司宣布，其基于下一代测序（NGS）的 clonoSEQ 测试将用于评估可测量的残留病（MRD），将在2024年12月7日至10日于圣地亚哥举行的第66届美国血液学会（ASH）年会上包含在65篇以上的摘要中。这些摘要中包括一次全体会议报告，一篇最新的摘要和25个其他的口头报告。
"We are inspired to see clonoSEQ MRD testing featured in a record-breaking number of studies at this year's ASH Annual Meeting," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. "The increasingly widespread use of clonoSEQ as a highly sensitive test to support clinical decision-making and as a primary endpoint in clinical trials highlights its multi-faceted role in advancing precision medicine in hematology."
“我们受到启发，看到 clonoSEQ MRD 测试在今年的 ASH 年会上以创纪录的数量被特色板块展示，”adaptive biotechnologies 的首席商业官、MRD 负责人苏珊·博布尔斯基说道。“clonoSEQ 作为一种高灵敏度测试在临床决策中越来越广泛的应用，以及作为临床试验的主要控件，突显了它在推进血液学精准医疗中的多方面作用。”
Multiple studies underscore the use of clonoSEQ as the standard for demonstrating efficacy in pivotal clinical trials and highlight advantages of leveraging the highest sensitivity in both clinical trials and real-world practice across various blood cancers. Notably, several practice-changing studies using MRD as a primary endpoint in multiple myeloma (MM), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL), as well as studies using MRD interventionally in acute lymphoblastic leukemia (ALL), MM, MCL, and CLL, further validate its critical role in assessing deep therapeutic responses and informing treatment decisions.
多项研究强调了将 clonoSEQ 作为在关键临床试验中证明疗效的标准，并突出了在各种血液肿瘤中利用最高灵敏度的临床试验和现实实践的优势。值得注意的是，多个以 MRD 作为主要控件的实践改变研究在多发性骨髓瘤（MM）、披衣细胞淋巴瘤（MCL）和慢性淋巴细胞白血病（CLL）中，及在急性淋巴细胞白血病（ALL）、MM、MCL 和 CLL 中进行的 MRD 介入研究进一步确认了其在评估深度治疗反应和指导治疗决策中的关键作用。
A complete list of the accepted abstracts featuring clonoSEQ is available here.
有关包含 clonoSEQ 的所有接受的摘要的完整列表可用 这里.
About clonoSEQ
clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ testing for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) patients is currently available for clinical use as a laboratory-developed test (LDT) performed at Adaptive's CLIA-certified lab in Seattle, WA. clonoSEQ is CE-marked under IVDR in the EU. For the approved intended use in the EU under IVDR, please refer to the instructions for use, available on request.
关于clonoSEQ
clonoSEQ是首个也是唯一一个获得FDA批准的体外诊断(IVD)测试，旨在检测多发性骨髓瘤(MM)或b型急性淋巴细胞白血病(b-ALL)患者的骨髓中的最小残留疾病(MRD)，以及慢性淋巴细胞白血病(CLL)患者的血液或骨髓。clonoSEQ目前可作为实验室开发测试(LDT)在实施于adaptive biotechnologies在华盛顿州西雅图的CLIA认证实验室中，对弥漫大B细胞淋巴瘤(DLBCL)和套细胞淋巴瘤(MCL)患者进行检测。clonoSEQ在欧盟根据IVDR进行了CE标记。有关IVDR下在欧盟批准的预期用途，请参阅可按要求提供的使用说明。
clonoSEQ leverages Adaptive Biotechnologies' proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The test provides standardized, accurate, and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to treatment, inform changes in therapy, monitor disease burden over time, and detect potential relapse early. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by the clonoSEQ in patients diagnosed with CLL, MM, ALL and DLBCL.
clonoSEQ利用adaptive biotechnologies的专有免疫医学平台来识别和定量恶性细胞中的特定DNA序列，使临床医生能够在治疗期间及之后评估和监测MRD。该测试提供标准化、准确和敏感的MRD测量，允许医生预测患者的结果，评估治疗反应，告知治疗更改，监测疾病负担随时间的变化，并早期检测潜在的复发。血液恶性肿瘤的临床实践指南认可MRD状态是临床结果和治疗反应的可靠指标，并且临床结果已被证明与通过clonoSEQ测量的患者MRD水平之间存在强关联，患者诊断为CLL、MM、ALL及DLBCL。
For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit .
有关clonoSEQ获得FDA批准的用途的重要信息，包括完整的预期用途，限制条件和详细的性能特征，请访问 .
About Adaptive Biotechnologies
Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
关于Adaptive Biotechnologies
Adaptive Biotechnologies（“我们”或“我们的”）是一家商业化生物技术公司，专注于利用适应性免疫系统的固有生物学，改变疾病的诊断和治疗。我们认为，适应性免疫系统是自然界中用于大多数疾病的最精细调节的诊断和治疗方法，但无法对其进行 解码阻止了医学界充分利用其能力。我们专利的免疫药物平台可以大规模、精确、迅速地揭示并翻译适应性免疫系统的巨大遗传信息。我们将这种方法应用于与生物制药公司的合作中，以推动药物的研发和临床诊断。我们的商业产品和临床管道使癌症、自身免疫性疾病和传染性疾病等疾病的诊断、监测和治疗成为可能。我们的目标是开发和商业化针对每个病人量身定制的免疫驱动的临床产品。
Forward Looking Statements
This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
前瞻性声明
本新闻发布包含基于管理层信念和假设以及目前可获得的信息的前瞻性陈述。 本发布中包含的所有陈述（除历史事实陈述外）都是前瞻性陈述，包括关于我们开发、商业化及实现市场接受我们当前及计划产品和服务的能力、我们的研发工作以及其他与我们的业务战略、资本使用、运营结果和财务状况，以及未来运营的计划和目标相关的事项的陈述。
In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
在某些情况下，您可以通过诸如“可能”、“将”、“能够”、“会”、“应该”、“期望”、“打算”、“计划”、“预期”、“相信”、“估计”、“预测”、“项目”、“潜在”、“继续”、“正在进行的”或这些术语的否定形式或其他类似术语来识别前瞻性声明，尽管并非所有的前瞻性声明都包含这些词。这些声明涉及风险、不确定性和其他因素，可能导致实际结果、活动水平、表现或成就与前瞻性声明所表达或暗示的信息大相径庭。这些风险、不确定性和其他因素在我们不时向证券交易委员会提交的文件中的“风险因素”、“管理层的财务状况与运营结果的讨论与分析”以及其他地方进行了描述。我们提醒您，前瞻性声明是基于我们当前已知的事实和因素的组合以及我们对未来的预测，而我们对此不能确定。因此，前瞻性声明可能不能被证明是准确的。本新闻稿中的前瞻性声明代表了我们截至本日期的观点。我们没有义务出于任何原因更新任何前瞻性声明，除非法律要求。
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE INVESTORS
投资者关系副总裁Karina Calzadilla
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
ADAPTIVE MEDIA
企业传媒副总裁Erica Jones
206-279-2423
media@adaptivebiotech.com
